LianBio Management

Management Kriterienprüfungen 1/4

LianBio's CEO ist Adam Stone , ernannt in Dec 2023, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.016% der Aktien des Unternehmens, im Wert von $5.53K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 0.5 Jahre bzw. 2.7 Jahre.

Wichtige Informationen

Adam Stone

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.02%
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.8yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Adam Stone (44 yo)

less than a year

Amtszeit

US$62,073

Vergütung

Mr. Adam Leo Stone is Chief Investment Officer & Head of Research of Perceptive Advisors LLC. He joined the Perceptive Advisors LLC in 2006. He serves as CEO & Director at Perceptive Capital Solutions Corp...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Konstantin Poukalov	Founder & Executive Chairman	4.8yrs	US$62.07k	0.016% $ 5.5k
Adam Stone	Interim CEO & Director	less than a year	US$62.07k	0.016% $ 5.5k
Ehong Gu	Interim CFO	less than a year	keine Daten	0% $ 0
Ji Chen	Senior VP & General Counsel	no data	keine Daten	keine Daten
Brianne Jahn	Chief Business Officer	2.8yrs	US$2.69m	keine Daten
Levvy Lv Eng	Senior VP & Global Head of Development	no data	keine Daten	keine Daten

0.6yrs

Durchschnittliche Betriebszugehörigkeit

40yo

Durchschnittliches Alter

Erfahrenes Management: LIAN.YDas Führungsteam des Unternehmens gilt nicht als erfahren ( 0.5 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Konstantin Poukalov	Founder & Executive Chairman	4.8yrs	US$62.07k	0.016% $ 5.5k
Adam Stone	Interim CEO & Director	4.8yrs	US$62.07k	0.016% $ 5.5k
Tassos Anastasios Gianakakos	Independent Director	3.9yrs	US$128.07k	0.34% $ 116.0k
Susan Silbermann	Independent Director	2.8yrs	US$121.44k	0.016% $ 5.5k
Neil Kumar	Director	4.8yrs	keine Daten	0% $ 0
Elliott Levy	Member of Scientific Advisory Board	2.3yrs	keine Daten	keine Daten
Mathias Hukkelhoven	Member of Scientific Advisory Board	2.3yrs	keine Daten	keine Daten
Wei Chen	Independent Director	2.3yrs	US$285.89k	0% $ 0
Zhao Yan	Member of Scientific Advisory Board	2.3yrs	keine Daten	keine Daten

2.8yrs

Durchschnittliche Betriebszugehörigkeit

54.5yo

Durchschnittliches Alter

Erfahrener Vorstand: LIAN.YDie Vorstandsmitglieder gelten nicht als erfahren ( 2.7 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

LianBio Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

LianBio Announces Chief Financial Officer Changes

LianBio Announces Chief Financial Officer Changes

Lianbio Announces Chief Executive Officer Changes

LianBio Announces the Resignation of Debra Yu, M.D. as President and Chief Strategy Officer, Effective January 1, 2023

Less than half of directors are independent

Less than half of directors are independent

Recent updates

LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index

With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy

LianBio Intends to File Form 25 with SEC

LianBio Announces Chief Financial Officer Changes

LianBio Announces Chief Financial Officer Changes

Lianbio Announces Chief Executive Officer Changes

Concentra Biosciences, LLC cancelled the acquisition of LianBio (NasdaqGM:LIAN) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

New major risk - Revenue and earnings growth

LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

Price target decreased by 19% to US$6.24

Forecast to breakeven in 2023

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

LianBio (NASDAQ:LIAN) Is In A Good Position To Deliver On Growth Plans

Lianbio Announces Marketing Approval of CAMZYOS®? (Mavacamten) in Singapore

LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in the Macau Special Administrative Region (SAR) of China

We're Hopeful That LianBio (NASDAQ:LIAN) Will Use Its Cash Wisely

Price target decreased to US$8.23

We Think LianBio (NASDAQ:LIAN) Can Afford To Drive Business Growth

LianBio Announces the Resignation of Debra Yu, M.D. as President and Chief Strategy Officer, Effective January 1, 2023

Less than half of directors are independent

Price target increased to US$12.00

LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors

LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

Companies Like LianBio (NASDAQ:LIAN) Are In A Position To Invest In Growth

Lianbio Completes Enrollment in Pivotal Phase 3 EXPLORER-CNTrial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients

Will LianBio (NASDAQ:LIAN) Spend Its Cash Wisely?

LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers

U.S. Food and Drug Administration Approves Camzyos (Mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Less than half of directors are independent

LianBio Announces Formation of Scientific Advisory Board

LianBio Appoints Wei Wei Chen to Board of Directors

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

Here's Why LianBio (NASDAQ:LIAN) Must Use Its Cash Wisely

Lianbio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

LianBio Announces Approval of Infigratinib Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China

No independent directors

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter